Winst gevend schreef op 28 februari 2024 13:58:
Vooruitlopend op wat komen gaat,
een korte terugblik met een beknopt overzicht van de naderende Pharming events.First 9 Months Joenja income/sales - regarding US patients aged 12+ during 2023. +$18 M
=========================================================================
Q1 2023 23 +tartup US , 23 patients (+23) on paid therapy $ 0,0M (start 150 identified)
Q2 2023 60 enrollments, 43 patients (+20) on paid therapy $ 3.8M (+ $ 3,8M ) +107 to go
Q3 2023 76 enrollments, 63 patients (+20) on paid therapy $ 6.5M (+ $ 2,7M ) +087 to go
Q4 2023 92 enrollments, 81 patients (+18) on paid therapy $ 7.7M (+ $ 1,2M ) +069 to go
=========================================================================
UPGRADED > 840 diagnosed APDS patients global markets targeted commercializations
UPGRADED >1100 patients identified in the US - regarding VUS, APDS related indications
EMA CHMP-final phase/decision of leniolisib approval, to be expected in March 2024
FDA positive phase 2 clinical trial plans - PTEN1, ALPS-FAS2, CTLA4 - Apr/Jun 2024
UK - AUS - CAN - ISR - JAP market approval requests pending estimated during 2024
The next Novartis milestone payment equals $ 5M, on annual net sales passing $ 50M
Iedereen fijne en heldere discussies gewenst voor alles wat binnenkort te gebeuren staat.